APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, the apoA-I:CIGB-258 (1:1) group showed the highest swimming ability around 25 ± 3% and 70 ± 5% at 30 min and 60 min post-injection, respectively (Figure 8A), suggesting that a combination of apoA-I and CIGB-258 exhibited synergistic anti-inflammatory activity to suppress paralysis and the acute toxicity posed by CML.